ArticleFood science & nutrition2025
Biochemical Studies on the Therapeutic Effect of
Article in Food science & nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- NanoformulatedNanomaterials (Basel, Switzerland) · 2026Article
- Determination of the Lethal Concentrations of Two Phenolic Acid Derivatives Originated From the Edible Red Marine Macroalga (Food science & nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Illegal melamine analogs are added to food to make it appear as though it contains more protein. These substances have negative impacts on both humans and animals in high quantities. The present paper examines how cobra venom shields rats from melamine-induced hepatotoxicity. The current study was conducted on six groups of adult male rats, as follows: group I (negative control): I.P. injected with distilled water, group II (SV10 μg/kg):I.P injected with 10 μg/kg cobra venom, group III (SV20 μg/kg): I.P. injected with 20 μg/kg cobra venom, group IV (melamine): orally 700 mg/kg melamine, group V (melamine + SV10 μg/kg): treated with 10 μg/kg cobra venom, group VI (melamine + SV20 μg/kg): treated with 20 μg/kg cobra venom. Treatment with snake venom ameliorated liver functions and increased apoptotic level marker Caspase-3, decreased anti-apoptotic level marker BAX. Also, decreased inflammatory level marker IL-2 and expression level of IL-10, INF-γ. treatment with snake venom ameliorated hepatotoxicity induced by melamine in albino rats.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.